These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 32917480)

  • 21. Impact of forced vital capacity loss on survival after the onset of chronic lung allograft dysfunction.
    Todd JL; Jain R; Pavlisko EN; Finlen Copeland CA; Reynolds JM; Snyder LD; Palmer SM
    Am J Respir Crit Care Med; 2014 Jan; 189(2):159-66. PubMed ID: 24325429
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Abnormal one-year post-lung transplant spirometry is a significant predictor of increased mortality and chronic lung allograft dysfunction.
    Paraskeva MA; Borg BM; Paul E; Fuller J; Westall GP; Snell GI
    J Heart Lung Transplant; 2021 Dec; 40(12):1649-1657. PubMed ID: 34548197
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of chronic lung allograft dysfunction, especially restrictive allograft syndrome, on the survival after living-donor lobar lung transplantation compared with cadaveric lung transplantation in adults: a single-center experience.
    Sugimoto S; Yamamoto H; Kurosaki T; Otani S; Okazaki M; Yamane M; Toyooka S; Oto T
    Surg Today; 2019 Aug; 49(8):686-693. PubMed ID: 30790054
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Restrictive allograft dysfunction rather than bronchiolitis obliterans syndrome had a major impact on the overall survival after living-donor lobar lung transplantation.
    Matsubara K; Otani S; Yamamoto H; Hashimoto K; Tanaka S; Shien K; Suzawa K; Miyoshi K; Yamamoto H; Okazaki M; Sugimoto S; Toyooka S
    Surg Today; 2024 Apr; 54(4):317-324. PubMed ID: 37523071
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapy options for chronic lung allograft dysfunction-bronchiolitis obliterans syndrome following first-line immunosuppressive strategies: A systematic review.
    Benden C; Haughton M; Leonard S; Huber LC
    J Heart Lung Transplant; 2017 Sep; 36(9):921-933. PubMed ID: 28662986
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CT at onset of chronic lung allograft dysfunction in lung transplant patients predicts development of the restrictive phenotype and survival.
    Dettmer S; Shin HO; Vogel-Claussen J; Westphal M; Haverich A; Warnecke G; Welte T; Wacker F; Gottlieb J; Suhling H
    Eur J Radiol; 2017 Sep; 94():78-84. PubMed ID: 28647206
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early extracorporeal photopheresis treatment is associated with better survival in patients with chronic or recurrent acute lung allograft dysfunction.
    Gautschi F; Vogelmann T; Ortmanns G; Knörr F; Steinack C; Hage R; Nägeli M; Schuurmans MM
    J Clin Apher; 2024 Jun; 39(3):e22128. PubMed ID: 38829041
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Disease progression in patients with the restrictive and mixed phenotype of Chronic Lung Allograft dysfunction-A retrospective analysis in five European centers to assess the feasibility of a therapeutic trial.
    Gottlieb J; Verleden GM; Perchl M; Valtin C; Vallee A; Brugière O; Bravo C
    PLoS One; 2021; 16(12):e0260881. PubMed ID: 34941934
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phenotyping Chronic Lung Allograft Dysfunction Using Body Plethysmography and Computed Tomography.
    Suhling H; Dettmer S; Greer M; Fuehner T; Avsar M; Haverich A; Welte T; Gottlieb J
    Am J Transplant; 2016 Nov; 16(11):3163-3170. PubMed ID: 27203799
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chronic Lung Allograft Dysfunction.
    Venado A; Kukreja J; Greenland JR
    Thorac Surg Clin; 2022 May; 32(2):231-242. PubMed ID: 35512941
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Donor-specific antibody characteristics, including persistence and complement-binding capacity, increase risk for chronic lung allograft dysfunction.
    Iasella CJ; Ensor CR; Marrari M; Mangiola M; Xu Q; Nolley E; Moore CA; Morrell MR; Pilewski JM; Sanchez PG; McDyer JF; Zeevi A
    J Heart Lung Transplant; 2020 Dec; 39(12):1417-1425. PubMed ID: 32981841
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Primary graft dysfunction grade 3 following pediatric lung transplantation is associated with chronic lung allograft dysfunction.
    Wong W; Johnson B; Cheng PC; Josephson MB; Maeda K; Berg RA; Kawut SM; Harhay MO; Goldfarb SB; Yehya N; Himebauch AS
    J Heart Lung Transplant; 2023 May; 42(5):669-678. PubMed ID: 36639317
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Spectrum of chronic lung allograft dysfunction pathology in human lung transplantation.
    Renaud-Picard B; Berra G; Hwang D; Huszti E; Miyamoto E; Berry GJ; Pal P; Juvet S; Keshavjee S; Martinu T
    J Heart Lung Transplant; 2024 Oct; 43(10):1701-1715. PubMed ID: 38663465
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BALF cytokines in different phenotypes of chronic lung allograft dysfunction in lung transplant patients.
    Berastegui C; Gómez-Ollés S; Sánchez-Vidaurre S; Culebras M; Monforte V; López-Meseguer M; Bravo C; Ramon MA; Romero L; Sole J; Cruz MJ; Román A
    Clin Transplant; 2017 Mar; 31(3):. PubMed ID: 28008659
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Significance of phenotype change after chronic lung allograft dysfunction onset.
    Fuchs E; Levy L; Huszti E; Renaud-Picard B; Berra G; Kawashima M; Takahagi A; Ghany R; Havlin J; McInnis MC; Keshavjee S; Singer LG; Tikkanen J; Chow CW; Martinu T
    Transpl Int; 2021 Dec; 34(12):2620-2632. PubMed ID: 34748217
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incidence and impact of chronic lung allograft dysfunction after lung transplantation - single-center 14-year experience.
    Nykänen A; Raivio P; Peräkylä L; Stark C; Huuskonen A; Lemström K; Halme M; Hämmäinen P
    Scand Cardiovasc J; 2020 Jun; 54(3):192-199. PubMed ID: 32148103
    [No Abstract]   [Full Text] [Related]  

  • 37. MiR-21 in Lung Transplant Recipients With Chronic Lung Allograft Dysfunction.
    Miyahara N; Benazzo A; Oberndorfer F; Iwasaki A; Laszlo V; Döme B; Hoda MA; Jaksch P; Klepetko W; Hoetzenecker K
    Transpl Int; 2021; 35():10184. PubMed ID: 35185369
    [No Abstract]   [Full Text] [Related]  

  • 38. The Lymphatic Phenotype of Lung Allografts in Patients With Bronchiolitis Obliterans Syndrome and Restrictive Allograft Syndrome.
    Traxler D; Schweiger T; Schwarz S; Schuster MM; Jaksch P; Lang G; Birner P; Klepetko W; Ankersmit HJ; Hoetzenecker K
    Transplantation; 2017 Feb; 101(2):310-315. PubMed ID: 27163544
    [TBL] [Abstract][Full Text] [Related]  

  • 39. T Cells Promote Bronchial Epithelial Cell Secretion of Matrix Metalloproteinase-9 via a C-C Chemokine Receptor Type 2 Pathway: Implications for Chronic Lung Allograft Dysfunction.
    Pain M; Royer PJ; Loy J; Girardeau A; Tissot A; Lacoste P; Roux A; Reynaud-Gaubert M; Kessler R; Mussot S; Dromer C; Brugière O; Mornex JF; Guillemain R; Dahan M; Knoop C; Botturi K; Pison C; Danger R; Brouard S; Magnan A;
    Am J Transplant; 2017 Jun; 17(6):1502-1514. PubMed ID: 27982503
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neutrophilic reversible allograft dysfunction (NRAD) and restrictive allograft syndrome (RAS).
    Verleden SE; Vandermeulen E; Ruttens D; Vos R; Vaneylen A; Dupont LJ; Van Raemdonck DE; Vanaudenaerde BM; Verleden GM
    Semin Respir Crit Care Med; 2013 Jun; 34(3):352-60. PubMed ID: 23821509
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.